Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry.
作者信息
Claret L, Han Kelong, Bruno R
机构信息
Clinical Pharmacology, Genentech/Roche, Marseille, France.
Clinical Pharmacology Modeling & Simulations, GlaxoSmithKline, Philadelphia, Pennsylvania, USA.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):225. doi: 10.1002/psp4.12163. Epub 2017 Apr 11.
Abstract
摘要
相似文献
1
Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry.
CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):225. doi: 10.1002/psp4.12163. Epub 2017 Apr 11.
2
Correction to: Model-based estimates of tumor growth inhibition metrics are time-independent: A reply to Mistry.
CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1422. doi: 10.1002/psp4.13209. Epub 2024 Jul 23.
3
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). 2022, , 5158".
J Clin Med. 2023 Jun 13;12(12):4017. doi: 10.3390/jcm12124017.
4
Development and Validation of a Prostate Biopsy Risk Calculator in Black Men.
J Urol. 2024 Feb;211(2):223-233. doi: 10.1097/JU.0000000000003774. Epub 2023 Nov 2.
5
Response to Mistry: Radiosensitivity index is not fit to be used for dose adjustments: A pan-cancer analysis.
Clin Oncol (R Coll Radiol). 2023 Sep;35(9):621-623. doi: 10.1016/j.clon.2023.04.009. Epub 2023 May 6.
6
Response to Mistry.
Nat Commun. 2021 Jan 12;12(1):329. doi: 10.1038/s41467-020-20175-3.
7
Response to Mistry: Radiosensitivity Index is Not Fit to be Used for Dose Adjustments: A Pan-Cancer Analysis.
Clin Oncol (R Coll Radiol). 2023 Jul;35(7):482. doi: 10.1016/j.clon.2023.04.002. Epub 2023 Apr 18.
8
Comparison of Trihalomethane exposure assessment metrics in epidemiologic analyses of reproductive and developmental outcomes.
J Expo Sci Environ Epidemiol. 2024 Jan;34(1):115-125. doi: 10.1038/s41370-023-00559-5. Epub 2023 Jun 14.
9
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.
J Natl Cancer Inst. 2015 Aug 21;107(11). doi: 10.1093/jnci/djv239. Print 2015 Nov.
10
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
BMC Cancer. 2016 Jul 13;16:473. doi: 10.1186/s12885-016-2455-2.
本文引用的文献
1
Time-Dependent Bias of Tumor Growth Rate and Time to Tumor Regrowth.
CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):587. doi: 10.1002/psp4.12145. Epub 2016 Nov 10.
2
Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.
CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):352-8. doi: 10.1002/psp4.12064. Epub 2016 Jul 12.
3
Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.
Am J Gastroenterol. 2015 Dec;110(12):1647-50. doi: 10.1038/ajg.2015.210. Epub 2015 Sep 1.
4
Reply to U.R. Mansmann et al and M.-W. An et al.
J Clin Oncol. 2013 Dec 1;31(34):4374-5. doi: 10.1200/JCO.2013.52.5733. Epub 2013 Oct 28.
Zotero 插件